Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Capivasertib and Fulvestrant for Patients with Aromatase Inhibitor-resistant Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer: Results from the Phase III CAPItello-291 Trial

November 28th 2023

Hope Rugo, MD reviews key data from the CAPItello-291 phase 3 trial recently presented at the San Antonio Breast Cancer Symposium in December 2022.

Dr Torres on Treatment With ADCs in Breast Cancer

November 28th 2023

Mylin A. Torres, MD, discusses using antibody-drug conjugates (ADCs) to treat patients with breast cancer.

Dr Ma on the Use of AKT Inhibitors vs PI3K Inhibitors in Breast Cancer

November 27th 2023

Cynthia Ma, MD, PhD, discusses the use of AKT inhibitors vs PI3K inhibitors in breast cancer.

Educating Community Specialists on Evolving Treatment Landscape

November 24th 2023

Experts in breast, lung, and gastric malignancies provide insights on multidisciplinary care in oncology and educating community specialists.

Future Outlook for Treating Breast and Lung Cancers

November 24th 2023

Medical oncologists discuss prospects and challenges in the breast and lung cancer treatment landscapes.

Novel Treatment Approaches Under Investigation for HER2+ mBC

November 23rd 2023

Joseph Gligorov, MD, emphasizes the impact of trastuzumab deruxtecan in HER2-positive breast cancer and explores its potential in HER2-low populations, and envisions a future where ADCs and immunotherapy will have a vital role in treatment, particularly in triple-negative breast cancer.

Reviewing Best Practices in the Surgical Management of Breast Cancer: Key Advances

November 21st 2023

In this third episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, discuss key advancements made in the surgical treatment of patients with breast cancer.

FDA Approves Companion Diagnostic for Capivasertib Plus Fulvestrant in Advanced HR+/HER2–Breast Cancer

November 21st 2023

The FDA has approved the FoundationOne® CDx for use as a companion diagnostic to identify patients with advanced hormone receptor–positive, HER2-negative advanced breast cancer who may be eligible for treatment with the combination of capivasertib and fulvestrant.

Dr Kalinsky on Remaining Treatment Questions in Breast Cancer

November 17th 2023

Kevin Kalinsky, MD, MS, discusses key takeaways from the 2023 Bridging the Gaps in Breast Cancer meeting, highlighting questions that continue to persist in the treatment of breast cancer.

Dr Basho on Treatment Considerations With ADCs in Breast Cancer

November 17th 2023

Reva K Basho, MD, discusses the use of antibody-drug conjugates across the spectrum of breast cancer subtypes at the 2023 Bridging the Gaps in Breast Cancer meeting.

Future Directions in Gastric Cancer Treatment

November 17th 2023

Specialists in gastric cancer look to the future treatment landscape and review ongoing research in the disease space.

Treatment Considerations With TROP2-Targeted Therapy

November 17th 2023

Clinical insights on best practices for treating patients with TROP2-targeted therapy.

FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+/HER2– Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

November 16th 2023

The FDA has approved capivasertib plus fulvestrant for the treatment of patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer harboring 1 or more PIK3CA, AKT1, or PTEN alterations, following progression on at least 1 endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.

Treatment Approaches for Patients With HER2+ mBC and Brain Metastases

November 16th 2023

Dr Joseph Gligorov discusses the management of brain metastases in patients with HER2-positive breast cancer, emphasizing tucatinib and trastuzumab as promising options.

Common Adverse Events With Second- and Third-Line Therapies in Patients With HER2+ mBC

November 16th 2023

Joseph Gligorov, MD, discusses the potential side effects of second- and third-line therapies for patients with HER2+ metastatic breast cancer and highlights the low-toxicity profile of tucatinib when combined with trastuzumab and capecitabine.

Dr Abdou on Sequencing CDK4/6 Inhibitors in HER2– Metastatic Breast Cancer

November 16th 2023

Yara Abdou, MD, discusses findings from the phase 2 MAINTAIN trial in patients with HER2-negative metastatic breast cancer, as well as the clinical implications of these trial results.

Dr Jhaveri on Unanswered Questions in Breast Cancer Care

November 16th 2023

Komal Jhaveri, MD, FACP, discusses unmet needs for patients with breast cancer, as well as ways to address these needs through discussion and collaboration.

Dr Conlin on Targeting CNS Metastases in the Treatment of Breast Cancer

November 15th 2023

Alison K. Conlin, MD, discusses the importance of targeting central nervous system metastases in the treatment of patients with breast cancer, highlighting ongoing treatment investigations for this population.

Dr Mamounas on Surgical De-Escalation Strategies in HER2+ Breast Cancers

November 15th 2023

Terry P. Mamounas, MD, discusses surgical de-escalation strategies in the treatment of patients with HER2-positive breast cancer.

Dr Bardia on the Continued Investigation of Elacestrant in ER+/HER2– Breast Cancer

November 15th 2023

Aditya Bardia, MD, MPH, discusses the continued investigation of oral selective estrogen receptor degraders in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.